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Abstract
Objectives
To describe changes over time in extent of idiopathic pulmonary fibrosis (IPF) at multidetec-
tor computed tomography (MDCT) assessed by semi-quantitative visual scores (VSs) and
fully automatic histogram-based quantitative evaluation and to test the relationship between
these two methods of quantification.
Methods
Forty IPF patients (median age: 70 y, interquartile: 62-75 years; M:F, 33:7) that underwent
2 MDCT at different time points with a median interval of 13 months (interquartile: 10-17
months) were retrospectively evaluated. In-house software YACTA quantified automatically
lung density histogram (10th-90th percentile in 5th percentile steps). Longitudinal changes in
VSs and in the percentiles of attenuation histogram were obtained in 20 untreated patients
and 20 patients treated with pirfenidone. Pearson correlation analysis was used to test the
relationship between VSs and selected percentiles.
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Results
In follow-up MDCT, visual overall extent of parenchymal abnormalities (OE) increased in
median by 5 %/year (interquartile: 0 %/y; +11 %/y). Substantial difference was found
between treated and untreated patients in HU changes of the 40th and of the 80th percen-
tiles of density histogram. Correlation analysis between VSs and selected percentiles
showed higher correlation between the changes (Δ) in OE and Δ 40th percentile (r=0.69;
p<0.001) as compared to Δ 80th percentile (r=0.58; p<0.001); closer correlation was found
between Δ ground-glass extent and Δ 40th percentile (r=0.66, p<0.001) as compared to Δ
80th percentile (r=0.47, p=0.002), while the Δ reticulations correlated better with the Δ 80th
percentile (r=0.56, p<0.001) in comparison to Δ 40th percentile (r=0.43, p=0.003).
Conclusions
There is a relevant and fully automatically measurable difference at MDCT in VSs and in
histogram analysis at one year follow-up of IPF patients, whether treated or untreated: Δ
40th percentile might reflect the change in overall extent of lung abnormalities, notably of
ground-glass pattern; furthermore Δ 80th percentile might reveal the course of reticular
opacities.
Introduction
Idiopathic pulmonary fibrosis (IPF) is a progressive and irreversible interstitial lung disease
(ILD) of unknown etiology with a heterogeneous clinical course [1]. Notably, IPF is the most
common form of idiopathic interstitial pneumonias with a median survival of 2.5–3.5 years
after diagnosis [2]. Recently, pirfenidone, an orally active, small molecule that inhibits synthesis
of pro-fibrotic and inflammatory mediators, was approved for the treatment of patients with
mild to moderate IPF in the European Union and other countries, as it demonstrated a signifi-
cant reduction of disease progression and a potential survival benefit [3, 4]. Furthermore,
another drug, nintedanib, showed efficacy in the treatment of IPF [5]. However, given the vari-
able course of the disease and the potential adverse effects associated with the substantial costs
of these treatments, it is crucial to objectively assess the progression of IPF, in order to identify
natural course and treatment effectiveness both in clinical practice and during clinical trials.
Although predictive markers of response to therapy are still missing, pulmonary
impairment, symptoms, and serial imaging changes are widely used in monitoring patients.
Forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide (DLCO)
are both recommended in monitoring IPF [1]. However, FVC quantification is sometimes
challenging in patients with dyspnea and cough and it might be demanding to differentiate
between significant changes that represent disease progression and measurement variability
[1, 6]. In addition DLCO is affected by underlying pulmonary vasculopathy and emphysema
[1, 7, 8].
In contrast, multidetector computed tomography (MDCT) is a potential alternative to
assess “in vivo” the progression of the disease [9]. Despite several MDCT features can be
observed in fibrotic interstitial lung disease (reticular pattern, traction bronchiectasis, ground
glass opacity, and honeycombing), agreement between readers about the presence and extent
of these basic patterns is variable [10–13]. Quantitative computed tomography has the poten-
tial advantages of objectivity and ability to identify features that are not visually recognizable.
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Histogram-based measurements showed moderate correlation with functional impairment
and demonstrated significant changes at one-year follow-up, indicating disease progression
[14–16]. In chronic obstructive pulmonary disease (COPD), the 15th percentile of lung density
histogram is regarded as a useful tool in detecting patients with emphysema [17]. It is therefore
hypothesized, that in patients suffering from IPF, specific percentiles of lung density histogram
might reflect the extension of MDCT abnormalities and might be considered a biomarker of
disease evolution.
The purposes of this study were to describe the changes over time in the extent of parenchy-
mal abnormalities assessed on chest MDCT by both semi-quantitative visual scores (VSs) and
automatic histogram-based quantitative analysis and to test the relationship between these two
methods of quantification of lung abnormalities in patients suffering from IPF.
Materials and Methods
Patients
All procedures were in accordance with the declaration of Helsinki. MDCTs were performed
on clinical indication. Informed written consent for examination was obtained from all
patients. Clinical records of 256 patients suffering from IPF admitted to our center for intersti-
tial and rare lung disease between August 2006 and December 2013 were reviewed retrospec-
tively. The retrospective analysis was approved by the ethics committee of the medical school
of the University of Heidelberg (IRB approval number S-318/2013). All patient records were
anonymized and de-identified prior to analysis.
The diagnosis of IPF was confirmed in each patient by a multidisciplinary team discus-
sion meeting (pulmonologists, radiologists, and pathologists experienced in the diagnosis
and treatment of IPF) and was based on a review of clinical data, chest MDCT, and histologi-
cal assessment of lung biopsies. IPF was diagnosed according to the current consensus state-
ment of the American thoracic society/European respiratory society/Japanese respiratory
society/Latin American Thoracic Association (ATS/ERS/JRS/ALAT) for patients with first
diagnosis after 2011, whereas prior cases were diagnosed following the previous guidelines
[1, 18]. Individual therapeutic schemes were selected on the basis of the interdisciplinary
statement.
Demographic and clinical data of the study population are shown in Table 1. A total of 40
patients that underwent 2 technically identical MDCT examinations on the same scanner sepa-
rated by an interval of at least 6 months (median interval between initial and follow-up MDCT:
13 months; interquartile: 10 months; 17 months) were enrolled consecutively. In order to assess
whether the range of detectable differences over time in MDCT lung density histogram was
measureable, a random population of 20 patients treated with pirfenidone, an anti-fibrotic
drug licensed for mild to moderate IPF, and another 20 patients not treated with this drug was
composed [19]. The interval time between the initial MDCT and the beginning of the pirfeni-
done therapy did not exceed about 1/3 of the interval between the initial and the follow-up
MDCT scans. Pirfenidone was not clinically indicated for several reasons in the remaining 20
patients [19]. To perform an accurate evaluation in longitudinal changes of lung attenuation
histograms, were excluded patients in which initial and follow-up MDCT scans were obtained
using different scanner, contrast application (i.e initial contrast-enhanced MDCT and not con-
trast-enhanced follow-up scan), or reconstructed with different algorithms (i.e filtered back
projection vs. iterative) [20]. Details about medical treatment between initial and follow-up
MDCTs are shown in Table 1.
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Table 1. Study population (n = 40) characteristics.
Sex [M/F] 33/7
Initial Age [years] 70 (62–75)
Initial body mass index (BMI) [kg/m2] 27 (24–30)
Relevant comorbidities
Pulmonary hypertension [number] 3/40
Fibrosis with emphysemaa [number] 13/40
Gastro-esophageal reflux disease [number] 6/40
Smoking History
Never [number] 12/40
Former smokers [number] 25/40
Current smokers [number] 3/40
Pack-years [years] 20 (10;36)
Diagnostic procedures
Definite usual interstitial pneumonia pattern on MDCT [number] 21/40
Surgical biopsy [number] 19/40
Interval IPF diagnosis and 1st MDCT [months] 13 (0–35)
Initial pulmonary function tests
VC [% predicted]b 71 (58;84)
TLC [% predicted]b 61 (58;82)
DLCO [% predicted]c 40 (28;57)
PaO2 [mmHg] 66 (63;72)
Initial O2 therapy [number] 6/40
Therapy prior initial MDCT
N-acetylcysteine only [number] 27/40
Steroids and N-acetylcysteine [number] 8/40
Combined immunosuppressive therapy (N-acetylcysteine, steroids, and immunomodulatord) [number] 5/40
Therapy between initial and follow-up MDCT
N-acetylcysteine only [number] 5/40
Steroids and N-acetylcysteine [number] 2/40
Combined immunosuppressive therapy (N-acetylcysteine, steroids, and immunomodulatord) [number] 13/40
Pirfenidone alone [number] 13/40
Pirfenidone and N-acetylcysteine [number] 1/40
Pirfenidone, N-acetylcysteine, and steroids [number] 3/40
Pirfenidone and steroids [number] 3/40
Sildenafil 1/40
Bosentan 1/40
Initial and follow-up MDCT interval [months] 13 (10–17)
Summary of gender, age, body mass index (BMI), smoking history, comorbidities, diagnostic procedures, pulmonary function tests [including vital capacity
(VC), total lung capacity (TLC), diffusing capacity of the lung for carbon monoxide (DLCO), and arterial pressure of oxygen (PaO2)], therapy prior and after
initial multidetector computed tomography (MDCT), and interval between initial and follow-up MDCT data of the idiopathic pulmonary fibrosis (IPF) patients
that constituted the study population. Data are presented as absolute number of patients (n) or median and interquartile range (in brackets).
aWas considered the presence or absence of emphysema additionally to fibrosis.
bOne value is missing due to patient inability to perform pulmonary function tests.
cSeven values are missing due to patient inability to perform the DLCO test.
dImmunomodulator indicates azathioprine and\or cyclophosphamide at a dosage clinically indicated.
doi:10.1371/journal.pone.0130653.t001
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Multidetector Computed Tomography
In all IPF patients, thin-section MDCT of the entire chest was routinely performed at inspira-
tory breath-hold in supine position using spiral mode scanning. Prior to the examination, all
patients were trained to achieve a full end-inspiratory breath-hold after automatic patient
instruction. Twenty-nine patients underwent the pair of baseline and follow-up MDCT scans
on a 4-slice scanner (Volume Zoom, Siemens AG, Forchheim, Germany) and 11 patients on a
64-slice scanner (Somatom Definition AS, Siemens AG, Forchheim, Germany). The technical
parameters for the 4-slice scanner were as follows: tube voltage 120 kV, effective tube current-
time product of 70 mAs, collimation of 4x1.25 mm, rotation time 0.5 sec, and pitch of 2 (typi-
cally DLPw = 127 mGy cm, E = 1.6 mSv, and scan time = 18 sec). The acquisition parameters
for the 64-slice scanner were as follows: tube voltage 120 kV, median effective tube current-
time product of 67 mAs (range 48–151), collimation of 64x0.6 mm, rotation time of 0.33 sec,
and pitch of 1.5 (typically DLPw = 37 mGy cm, E = 0.6 mSv, and scan time = 3 sec). Two
patients were scanned both at baseline examination and at follow-up with contrast enhanced
MDCT on the 4-slice scanner with identical administration (120ml Iopamidol-300, Bracco
Imaging, Konstanz, Germany @ 3.5ml/s). Baseline and follow-up scans were started automati-
cally by bolus triggering with a region-of-interest (ROI) located in the pulmonary trunk, and
scanning protocol as mentioned above.
Image reconstruction was performed with a slice thickness of 1.25 and 1 mm increment.
Since medium-soft kernels are more accurate and less noisy than sharp kernels for computer
based quantitative analysis, either B40f kernel (4-slice scanner) or iterative I40f algorithm
(64-slice scanner) were used [15]. The scale of attenuation coefficients with these systems ran-
ged from -1024 HU to +3071 HU. The systems were calibrated with a standard phantom for
water in quarterly period and after major maintenance, as well as for air daily. MDCT scans
affected by severe respiratory artifacts were not encountered in this study.
Visual scoring and automatic evaluation at MDCT
MDCT images for each patient were reviewed by a trainee (D.C.) with 2 year of experience in
thoracic imaging, who was blinded to individual therapy, clinical findings and histological
data, after 6 months of focused training for ILD under interactive guidance of experienced
chest radiologists (C.P.H and J.D.). For each patient, all the MDCT scans were scored on a cer-
tified PACS workstation simultaneously, using a window setting for lung parenchyma (center,
-600 HU; width, 1600 HU).
MDCT scans were visually evaluated at six axial levels selected by the reader as follows: 1)
the aortic arch, 2) the carina, 3) the pulmonary venous confluence, 4) the midpoint between
level 3 and level 5, 5) 1 cm above the dome of the right hemi-diaphragm and 6) 2 cm below the
dome of the right hemi-diaphragm [21]. MDCT findings were interpreted on the basis of the
recommendations suggested by the Fleischner Society nomenclature committee [10]. The
reader quantified semi-quantitatively in each slice the overall extent of interstitial lung disease
(OE), defined by the sum of ground glass opacities (GGO), reticular opacities (RET), honey-
combing (HC), and consolidations (CONS). Afterwards the reader quantified in each slice the
individual amount of GGO, RET, HC, CONS and emphysema (EMP). Each score was calcu-
lated as the percentage of lung parenchyma involved to the nearest 5%. In each patient, the
total extent of OE, GGO, RET, HC, CONS and EMP were derived by averaging the scores
obtained at the six axial levels described above.
The lung density histogram of each CT was obtained using the in-house YACTA software,
which was primarily developed for the emphysema quantification [22]. The stack of around
300 DICOM images per patient was analyzed fully automatically in an unattended mode. Soft
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tissues (> -750 HU), lungs (< -500 HU), and tracheobronchial tree were found fully automati-
cally using both threshold values and anatomical knowledge-based algorithms without manual
interaction (Fig 1). In each MDCT the reader assessed the quality of the volume automatically
segmented. The HU value of the range 10th-90th percentile in 5th percentiles steps was derived
from the histogram recording the densities of all lung voxels for each MDCT.
Pulmonary function tests
Body plethysmography (MasterScreen Body; E. Jaeger, Hoechberg, Germany) was performed
according to the guidelines of the ERS and the standards of the ATS [23]. Pulmonary function
tests (PFTs) were obtained within 30 days of MDCT scans. The European Coal and Steel Com-
munity—predicted values were selected as our in-house standard and reflect the individually
measured value in relation to an age- and height-matched control population given in percent-
age [24]. The “%” symbol following the PFT parameters indicates the predicted values in per-
cent. The changes in both vital capacity (VC%) and diffusing capacity of the lung for carbon
monoxide (DLCO%) between the initial and the follow-up PFTs were used for the correlation
analysis [1].
Fig 1. Visualization of the fully automatic lung parenchyma segmentation as obtained by in-house
YACTA software. Sagittal reconstruction image of a non-enhanced MDCT scan obtained from a patient
suffering from idiopathic pulmonary fibrosis (IPF) not included in the current trial. YACTA software
automatically segmented lung parenchyma and trachea-bronchial tree, emphasized as green and orange
overlay respectively (window width: 1600 HU; level: -600 HU). Note that the segmentation algorithm fails to
segment portions of the lung parenchyma in the sub-pleural space of the recessus, due to its similar density
to the chest wall. (MDCT = multidetector computed tomography).
doi:10.1371/journal.pone.0130653.g001
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Data evaluation and statistical analysis
Individual longitudinal changes per year in VSs (Δ VSs %/y), in every 5th percentile included in
the range of 10th-90th percentile of lung density histogram (Δ PERC HU/y), and in PFTs (Δ
PFTs %/y) were computed as the difference between the initial and follow-up MDCTs results
divided by the interval. In order to identify a measurable difference in MDCT density, the per-
centiles of the attenuation histogram characterized by the largest difference and the lowest
overlap in longitudinal HU changes between treated and untreated patients were identified.
Pearson correlation analysis was used to evaluate the relationship between VSs, selected PERC,
and PFTs%. All data were recorded using a dedicated database (Excel 2010, Microsoft Corp.,
Redmond, WA) and analyzed using SPSS version 20 (SPSS, Inc., Chicago, IL). A p value less
than 0.05 was considered significant.
Results
Visual scoring and automatic evaluation at MDCT
Table 2 summarizes both baseline and sequential VSs changes per year (Δ VSs). At follow-up
MDCT, the OE increased in median of 5%/y (interquartile: 0%/y; +11%/y). Regarding individ-
ual pattern, RET and HC extent showed a median increment of 2%/y (interquartile: -1%/y;
+5%/y) and 1%/y (interquartile: 0%/y; +2%/y) respectively; in addition GGO (median: 0%/y;
interquartile: -2%/y; +3%/y), and CONS (median: 0%/y; interquartile: 0%/y; 0%/y) extents
were stable., Twenty-seven patients showed no signs of emphysema at baseline. Thirteen
patients manifested emphysema at MDCT regardless the percentage of parenchyma involved.
Excluding 2/13 patients with an emphysema visual score of 18% and 24%, the remaining 11/13
patients manifested a maximum amount of emphysema of 8%.
For each MDCT the volume automatically segmented was considered satisfactory by the
reader. Fig 2 shows the median HU increase over 1-year in each 5th percentile included in the
Table 2. Visual scores obtained at multidetector computed tomography (MDCT).
Initial MDCT
overall extent [%] 32 (23;51)
ground-glass opacities [%] 6 (2;15)
reticular opacities [%] 20 (14;29)
honeycombing [%] 1 (0;3)
consolidations [%] 0 (0;0)
emphysema [%] 0 (0;3)
Longitudinal changes at 1-year follow-up (Δ)
Δ overall extent [%/y] +5 (0;+11)
Δ ground-glass opacities [%/y] 0 (-2;+3)
Δ reticular opacities [%/y] +2 (-1;+5)
Δ honeycombing [%/y] +1 (0;+2)
Δ consolidations [%/y] 0 (0; 0)
Δ emphysema [%/y] 0 (0;0)
Summary of the visual scores, expressed as percent of parenchyma involved (%), obtained at initial
multidetector computed tomography (MDCT) and their longitudinal changes at 1-year (Δ), expressed as
percent per year (%/y). Ground-glass opacities, reticular opacities, honeycombing, consolidations, and
emphysema were defined according to the recommendations suggested by the Fleischner Society
nomenclature committee [10]. Data are expressed as median and interquartile ranges (in brackets).
doi:10.1371/journal.pone.0130653.t002
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range 10th-90th percentile of lung density histogram for both treated and untreated patients.
The largest difference with the lowest overlap between treated and untreated patients in longi-
tudinal HU changes of the attenuation histogram was detected in the 40th and in the 80th per-
centiles. The initial median density of the 40th percentile was -822 HU (interquartile: -861 HU;
-777 HU), while the 80th percentile showed a median density of -595 HU (interquartile: -674
HU; -518 HU); at follow-up MDCT, the 40th percentile demonstrated a median increase of 22
HU (interquartile: -3 HU; +37 HU) and the density of the 80th percentile increased of 35 HU
(interquartile: -3 HU; +65 HU). In particular, the median HU change of the 40th percentile was
of 12 HU (interquartile: -3 HU; +39 HU) in patients with the anti-fibrotic treatment and equal
to 26 HU (interquartile: -7 HU; +37 HU) in patients without specific anti-fibrotic therapy (Fig
3a). In the 80th percentile (Fig 3b), patients treated with pirfenidone showed a median density
increment of 28 HU (interquartile: -5 HU; +59 HU) whereas the median density increase in
patients without specific anti-fibrotic therapy was 44 HU (range: -3 HU; +70 HU).
Pulmonary function tests
The median VC% impairment was 4%/y (interquartile: -10%/y; +2%/y), while the reduction of
DLCO% was 2%/y (range: -13%/y; +2%/y). Due to worsening of the respiratory symptoms, the
follow-up VC% was not obtained in 2/40 patients, whereas follow-up DLCO%measurement
was not performed in 7/40 patients for the same reason.
Fig 2. Median density changes at 1-year follow-up in the range of 10th-90th percentile of the MDCT
attenuation histogram for patients suffering from idiopathic pulmonary fibrosis (IPF) treated and
untreated with pirfenidone. The largest difference with the lowest overlap between treated and untreated
patients in longitudinal HU changes of the attenuation histogram was detected in the 40th and in the 80th
percentiles. Black squares = median increase of each 5th percentile step included in the 10th-90th range of the
lung density histogram for patients treated with pirfenidone; black triangles and circles = interquartile range of
the increase in each 5th percentile step included in the 10th-90th range of the lung density histogram for
patients treated with pirfenidone; grey squares = median increase of each 5th percentile step included in the
10th-90th range of the lung density histogram for patients not treated with pirfenidone; grey triangles and
circles = interquartile range of the increase in each 5th percentile step included in the 10th-90th range of the
lung density histogram for patients not treated with pirfenidone. (Δ HU/y = changes in Hounsfield units per
year; MDCT = multidetector computed tomography).
doi:10.1371/journal.pone.0130653.g002
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Correlation analysis
The Pearson correlation coefficient between the selected percentiles of lung density histogram
and VSs are given in Table 3. The Δ OE showed a greater correlation with the Δ 40th PERC
(r = 0.69, p< 0.001; Fig 4a), as compared to the Δ 80th PERC (r = 0.58, p< 0.001). Addition-
ally, the Δ 40th PERC correlated more tightly with the Δ GGO (r = 0.66, p< 0.001; Fig 4b) as
compared to the remaining abnormalities. Conversely, the Δ 80th PERC demonstrated higher
correlation with the Δ RET (r = 0.56, p< 0.001; Figs 4c and 5) relative to the other patterns.
The ΔHC demonstrated a significant correlation with the Δ 40th PERC (r = 0.48, p = 0.002),
whereas no significant correlation was observed between the same pattern and the variation of
lung density in the 80th percentile.
The correlation coefficients obtained between the selected percentiles of lung density histo-
gram, VSs, and PFT% are listed in Table 4. The Δ VC% showed a negative, good correlation
with Δ OE (r = -0.63, p< 0.001). However, both the Δ GGO (r = -0.36, p = 0.031) and Δ RET
(r = -0.43, p = 0.005) extent demonstrated a significant but weak negative relationship with the
Δ VC%. Changes in HC extent was not significantly correlated with Δ VC%. The Δ VC% dem-
onstrated a similar negative correlation with both the Δ 40th PERC (r = -0.58, p< 0.001) and
the Δ 80th PERC (r = -0.57, p< 0.001). The Δ VSs and ΔDLCO% were not significantly corre-
lated, while was found a significant, although weak, relationship between Δ DLCO % and Δ
40th PERC (r = -0.48, p = 0.008) as well as with Δ 80th PERC (r = -0.40, p = 0.028).
Discussion
This study describes the intra-individual changes over 1 year in a visual and a fully automatic
histogram-based quantitative evaluation of MDCT in patients suffering from IPF. The visual
assessment of the follow-up MDCT demonstrates an increase in the overall extent of the dis-
ease with a predominant increment of the fibrotic abnormalities. Changes in the density values
of the 40th and the 80th percentile of the MDCT attenuation frequency histogram were identi-
fied as promising parameters for monitoring the disease extent. The correlation analysis
Fig 3. Distribution of the density changes at 1-year in the selected percentiles from the MDCT
attenuation histogram of patients suffering from idiopathic pulmonary fibrosis (IPF) treated and
untreated with pirfenidone. Box andWhisker plots represent the 40th percentile (a) and the 80th percentile
distributions (b) of lung density histogram as observed in patients treated with pirfenidone and in patients not
treated with pirfenidone. The central line represents the median, the yellow box encompasses the 25th-75th
percentiles, whiskers show the 10th-90th percentile, and the empty circles represent individual outliers. (HU/
y = Hounsfield units per year; Δ 40th percentile = changes at 1-year in the 40th percentile of the attenuation
histogram; Δ 80th percentile = changes at 1-year in the 80th percentile of the attenuation histogram;
MDCT = multidetector computed tomography).
doi:10.1371/journal.pone.0130653.g003
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between changes after 1 year in VSs and in selected percentiles suggested that the 40th percen-
tile of lung density histogram, representing the low-density parenchymal areas (i.e. 40% of all
lung voxels are of lower density while 60% are of higher density), might reflect the overall
extension of the abnormalities, including the GGO, which hypothetically represents potentially
reversible acute inflammation [25, 26]. Additionally, the 80th percentile of attenuation histo-
gram, representing the high-density parenchymal areas (i.e. 80% of all lung voxels are of lower
density while 20% are of higher density), might reveal the progression of the reticular opacities.
Since visual assessment is time-consuming, suffers from low reproducibility and even intra-
individual variation, it is consecutively not used in clinical routine [11–13]. The role of quanti-
tative MDCT indexes of interstitial lung diseases is challenging in this high-contrast organ,
consisting of low and high-density compartments [16]. In patients suffering from IPF, the his-
togram-based approach was used more extensively and showed a reasonable correlation with
the pulmonary function tests [14]. In a previous study, skewness and kurtosis of MDCT attenu-
ation histograms were used as quantitative indexes and their changes over time suggested that
these parameters might be used to identify progression of fibrosis [16]. However, skewness
and kurtosis are not “user friendly” in the clinical routine [27]; additionally, in a recent study
of Kim et al., longitudinal changes in kurtosis were not associated with FVC and DLCO
impairment [28]. Therefore, in the present study, a novel and easier approach was introduced
for the automatic estimation of disease progression, based on density changes of selected per-
centiles derived from the MDCT lung density histogram. The lung density increase in the 80th
percentile of frequency histogram was of about 30–40 HU, in contrast to an increment of 10–
20 HU detected in the 40th percentile. Especially changes in the 80th percentile are of a signifi-
cant amount, which is crucial in a high-contrast organ such as the lung, whose density is also
influenced by different respiratory levels. In the majority of cases, the MDCT abnormalities
detected in IPF patients consisted of mixed ground-glass opacities, reticulations and honey-
combing that resulted in a wide range of attenuation values for the respective pattern. For
Table 3. Correlation analysis between selected percentiles of multidetector computed tomography (MDCT) attenuation histogram and visual
scores (VSs).
Initial MDCT
VSs 40th percentile [HU] p value 80th percentile [HU] p value
OE [%] 0.79 <0.001 0.75 <0.001
GGO [%] 0.52 0.001 0.32 0.002
RET [%] 0.64 <0.001 0.67 <0.001
HC [%] 0.16 0.312 0.26 0.091
Longitudinal changes at 1-year follow-up (Δ)
Δ VSs Δ 40th percentile [HU/y] p value Δ 80th percentile [HU/y] p value
Δ OE [%/y] 0.69 <0.001 0.58 <0.001
Δ GGO [%/y] 0.66 <0.001 0.47 0.002
Δ RET [%/y] 0.43 0.003 0.56 <0.001
Δ HC [%/y] 0.48 0.002 0.27 0.091
Summary of correlation analysis between visual scores (VSs) and selected percentiles obtained from multidetector computed tomography (MDCT)
attenuation histogram at initial MDCT and at 1-year follow-up. Pearson r coefficients were calculated for overall extent of abnormalities (OE), ground-glass
opacities extent (GGO), reticulations extent (RET), and honeycombing extent (HC), expressed as percent of parenchyma involved (%), with the density,
expressed as Hounsfield Unit (HU), of both the 40th and the 80th percentiles obtained from the MDCT attenuation histogram at baseline. The same
coefficients were obtained for longitudinal changes at 1-year (Δ) in VSs, expressed as percent per year (%/y), with the variation in density, expressed as
Hounsfield Unit per year (HU/y), of both the 40th and the 80th percentiles obtained from the MDCT attenuation histogram. In bold p values statistically
significant (p<0.05).
doi:10.1371/journal.pone.0130653.t003
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Fig 4. Correlations between changes at 1-year in selected percentiles of MDCT attenuation histogram
and visual scores. Dot plots with linear regression curves for changes in overall extent of parenchymal
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abnormalities plotted against density variation in the 40th percentile of the MDCT attenuation histogram
(r = 0.69, p < 0.001) (a), for the changes in ground-glass opacity extent plotted against density variation in the
40th percentile of the MDCT attenuation histogram (r = 0.66, p < 0.001) (b), and for changes in reticulations
extent plotted against density variation in 80th percentile of the MDCT attenuation histogram (r = 0.56,
p < 0.001) (c). (%/y = percent per year; HU/y = Hounsfield units per year; MDCT = multidetector computed
tomography).
doi:10.1371/journal.pone.0130653.g004
Fig 5. Variation of disease extent at follow-up MDCT in a 53 years-old man suffering from idiopathic pulmonary fibrosis (IPF) not treated with
pirfenidone. Axial MDCT image at level 5 (1 cm above the right hemi-diaphragm as described in the text) of the initial examination shows mild reticular
opacities and minimal honeycombing (arrowheads) in a sub-pleural distribution (a). The 80th percentile of the initial MDCT attenuation histogram
corresponded to -730 HU (b). Follow-up MDCT scan at the same axial level after 17 months shows a predominant increase of reticulations (visual score =
+22%) and unmodified honeycombing extent (arrowhead) (c). An increase of 86 HU in the density of the 80th percentile was seen between initial and follow-
up MDCT attenuation histograms (d). (Prob. = probability; HU = Hounsfield units; MDCT = multidetector computed tomography).
doi:10.1371/journal.pone.0130653.g005
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instance, an increase of the gross cystic changes results in a decrease of the average regional
HU values, possibly due to the air inside the cysts, in contrast to an increment of reticular opac-
ities and ground-glass opacities extents that causes an increase of the MDCT attenuation [29].
For this reason, the increase of the 80th percentile lung density, which represented the reticular
opacities progression, was higher as compared to the increment observed in the 40th percentile,
which probably reflected a combination of a predominant ground-glass pattern mixed with
reticular opacities and honeycombing. Similarly to the findings obtained by Yoon et al., in this
study a relatively good correlation was demonstrated between the automatic and the visual
quantification of the lung abnormalities extent, though higher correlation was seen between
the visual score of reticulations and correspondent automatic quantification (Table 3) [13].
Furthermore, in another series the association between the visual and the automatic quantifica-
tion of fibrotic pattern was weak [9]. For these reasons, the automatic quantification based on
density changes of selected percentiles derived from attenuation histogram might be more reli-
able in distinguishing the different IPF abnormalities than Gaussian histogram normalized cor-
relation (GNHC) and texture analysis based on statistical descriptors of frequency histogram
(i.e mean, standard deviation, skewness and kurtosis) used in the above mentioned studies [9,
13, 30].
The assessment of the relationship between MDCT features and functional status is chal-
lenging. MDCT is unable to quantify the absolute severity of inflammatory and fibrotic disease
Table 4. Correlation analysis of pulmonary function tests (PFTs) with visual scores (VSs) and
selected percentiles obtained frommultidetector computed tomography (MDCT) attenuation
histogram.
VSs, PERC VC [%] p value DLCO [%] p value
OE [%] -0.57 <0.001 -0.49 0.004
GGO [%] -0.45 0.004 -0.36 0.038
RET [%] -0.31 0.053 -0.23 0.207
HC [%] -0.05 0.754 -0.56 0.001
40th percentile [HU] -0.51 0.001 -0.50 0.003
80th percentile [HU] -0.56 <0.001 -0.62 <0.001
Δ VSs, Δ PERC Δ VC [%/y] p value Δ DLCO [%/y] p value
Δ OE [%/y] -0.63 <0.001 -0.16 0.395
Δ GGO [%/y] -0.36 0.031 -0.04 0.839
Δ RET [%/y] -0.43 0.005 -0.25 0.189
Δ HC [%/y] -0.23 0.156 +0.05 0.783
Δ 40th percentile [HU/y] -0.58 <0.001 -0.48 0.008
Δ 80th percentile [HU/y] -0.57 <0.001 -0.40 0.028
Summary of correlation analysis between pulmonary function tests (PFTs), visual scores (VSs), and
selected percentiles (PERC) obtained from multidetector computed tomography (MDCT) attenuation
histogram at initial MDCT and at 1-year follow-up. Pearson r coefficients were calculated for overall extent
of abnormalities (OE), ground-glass opacities extent (GGO), reticulations extent (RET), honeycombing
extent (HC) [all expressed as percentage of parenchyma involved (%)], and the density, expressed as
Hounsfield Unit (HU), of selected percentiles obtained from the MDCT attenuation histogram with the
percent predicted (%) of vital capacity (VC) and of diffusing capacity of the lung for carbon monoxide
(DLCO) at baseline. The same coefficients were obtained for both longitudinal changes at 1-year (Δ) in
VSs, expressed as percent per year (%/y), and in the density, expressed as Hounsfield Unit per year (HU/
y), of selected percentiles obtained from the MDCT attenuation histogram with the variation, expressed as
percent predicted per year (%/y), of VC% and of DLCO%. In bold p values statistically significant (p<0.05).
doi:10.1371/journal.pone.0130653.t004
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[29]. However, the correlation with both the VC% and the DLCO% decline achieved by
changes of histogram attenuation in the selected percentiles were higher than the relationship
observed in previous studies between statistical descriptors of lung density histogram (mean,
standard deviation, skewness and kurtosis) and the functional impairment [13–15]. These
results confirmed that histogram analysis based on the selected percentiles do better represent
the decline of lung function over time than the investigation of the other frequency histogram
features above mentioned.
There are several limitations in this study besides those already described above. First, it is a
retrospective data analysis on a small number of patients from a single center. However, the
presence of patients from only one center reduced the inter-scanner variability, which is a well-
known drawback and limitation of any quantitative analysis and especially the automatic eval-
uation [14]. Second, no spirometric gating in the acquisition of chest MDCT images was used,
but each patient was trained to achieve a full end-inspiratory breath-hold. Also, Best et al. sug-
gested that spirometric standardization might not be necessary for routine use [16]. Third,
visual scores at CT were obtained by a single not-experienced reader. However, it is well-
known that visual assessment suffers from inter-individual and even intra-individual variation,
thus the visual analysis was not based upon a multi-reader special-expert board, but upon a
constant focus trained single reader under interactive guidance of experienced chest radiolo-
gists [11–13]. In addition, correlations with percentiles obtained in the present study were
good, therefore they are expected higher if visual scores are obtained by experienced readers.
Fourth, there is a weakness in the automatic segmentation provided by the in-house software,
which was initially developed for emphysema quantification with corresponding algorithms
for lung contour detection. The software expected a low-density lung parenchyma while IPF-
patients show a high-density lung parenchyma, leading to possible failures in the segmentation
of the sub-pleural regions. Since IPF manifests to a relevant amount in the sub-pleural space,
the segmentation algorithm fails to include parts of the affected lung as seen in a patient not
included in this trial shown in Fig 1. This requires more sophisticated segmentation algorithms
that take anatomical knowledge (rib, liver, etc.) into account and\or allow manual correction of
the segmented volume. Such tools are under development but were not implemented in the
YACTA software at the study time. This might have caused an underrepresentation of the
high-density parts of the disease leading to higher values of e.g. the 80th percentile. However,
during the planning phase of a software manual correction tool, was found a difference of 70
ml (around 1–2% of the total lung volume) between the manual and the fully automatic seg-
mentation volume. This difference might be regarded marginal considering that might be
nearly constant in the longitudinal MDCTs during the course of the disease. Fifth, the CT mea-
surements were not corrected for eventually different lung volumes. This would affect density
measures significantly. Neither the visual scores, nor the attenuation percentiles were normal-
ized for lung volumes. This should not affect the correlations results obtained in the present
study between such methods of quantification. However, for future studies lung volume nor-
malization is required, in order to eliminate the well-known limitation of sub-optimal inspira-
tion during MDCT scan [31]. Sixth, the patients analyzed were treated or untreated resulting
in very small subgroups. Since the purpose of this analysis was not to show treatment success
but only whether a follow-up can be quantified automatically, the included population was
chosen as it happens nowadays in clinical routine. This includes treated and untreated patients
with the aim of keeping the CT technology constant. Seventh, our study population included
two patients who underwent contrast-enhanced MDCT scans in order to mirror the typical
clinical environment. Iodinated contrast medium affects the lung attenuation [32]. However,
to reduce this limitation, both baseline and follow-up MDCTs scan were obtained with identi-
cal bolus triggering technique on the same scanner. Lastly, MDCT lung attenuation could be
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affected by congestive hearth failure and pulmonary embolism, which determine significant
alterations of the lung density histogram, such as a shift to higher HU values or a reduction of
skewness and kurtosis [33, 34]. However, in the present study, the patients were regularly
screened by echocardiography and hematic levels of brain natriuretic peptide (BNP). None of
them suffered from congestive heart failure or pulmonary embolism at MDCT time.
Conclusions
Visual quantification of parenchymal abnormalities at multidetector computed tomography
over 1 year in IPF patients showed an increase in the overall extent of the disease, with a pre-
dominant increment of the fibrotic abnormalities. The density changes in the 40th percentile
might reflect the overall extension of the lung abnormalities, in particular of the ground-glass
pattern, which could represent potentially reversible acute inflammation; in addition, the
change in the 80th percentile might reveal the progression of the irreversible fibrotic reticular
opacities. Future studies with a larger number of patients might focus upon these values.
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